Lymphoma, Primary Cutaneous Anaplastic Large Cell - 8 Studies Found
Withdrawn |
: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma : Lymphoma, Large-Cell : 2006-03-01 : Drug: MDX-060 |
Completed |
: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma : Large Cell Lymphoma : 2004-12-10 : Drug: SGN-30 |
Active, not recruiting |
: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma :
|
Completed |
: Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma :
|
Active, not recruiting |
: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) :
|
Recruiting |
: Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma :
: |
Recruiting |
: Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency :
|
Recruiting |
: Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides :
: Genetic: Genetically modified T cells # 1138 |